XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor

Table 2 Cox proportional hazards model for prognostic factors analysis in neuroblastoma patients (TMA)

Variables	Favorable/Unfavorable	Univariate analysis		Multivariate analysis
Variables	Favorable/Unfavorable	HR (95% CI)	P value	HR (95% CI)	P value
Gender	female /male	0.893 (0.430–1.856)	0.762
Age (month)	≤ 18/ > 18	2.549 (1.083–5.997)	0.032	2.029 (0.778–5.289)	0.148
Pathological histotype	ganglioneuroblastoma/ neuroblastoma	0.538 (0.249–1.161)	0.114
MYCN amplification	no/yes	6.973 (2.880–16.878)	< 0.001	3.299 (1.097–9.923)	0.034
Preoperative chemotherapy	no/yes	5.219 (2.200–12.382)	< 0.001	1.144 (0.297–4.406)	0.845
Tumor stage (INSS)	4 s + 1 + 2/3 + 4	8.691 (3.397–22.237)	< 0.001	2.676 (0.780–9.180)	0.118
XPO1 expression	low/high	10.652 (4.330–26.204)	< 0.001	4.392 (1.641–11.754)	0.003

Cox regression was used for statistical analysis. 95%CI 95% confidence interval, HR Hazard ratio, INSS International Neuroblastoma Staging System

ISSN: 1756-9966